NEW YORK (GenomeWeb) – Affymetrix reported after the close of the market Thursday that its first quarter revenues increased around 7 percent year over year and beat the consensus Wall Street estimate.

The microarray firm generated total revenues of $83 million for the three months ended March 31, compared to $77.9 million for Q1 2013. On average, analysts estimated revenues of $81.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.